Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome

Gao,Jingguo

doi:10.3892/etm.2013.1101

Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome

Authors:
- Jingguo Gao
View Affiliations

Affiliations: Department of Digestive System, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China
Published online on: May 8, 2013 https://doi.org/10.3892/etm.2013.1101
Pages: 93-96

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the correlation between anxiety-depression status and cytokines in diarrhea‑predominant irritable bowel syndrome (IBS-D). IBS-D patients were divided into an anxiety-depression IBS-D group and a non-anxiety-depression IBS-D group. Patients without IBS, anxiety or depression were selected as the control group. Scoring was performed using the self‑rating anxiety scale (SAS) and self-rating depression scale (SDS). Levels of IL-1β and IL-10 in the blood and sigmoid colon mucosa were detected, and the proportions of IL-1β‑ and IL-10‑positive cells in the sigmoid colon mucosa were determined. The results demonstrated that the SDS and SAS scores in the IBS-D group were significantly higher than those in the control group (P<0.05). The levels of IL-1β in the blood and sigmoid colon mucosa and the proportion of IL-1β‑positive cells in the sigmoid colon mucosa in the IBS-D group were significantly higher than those in the control group (P<0.05). The levels of IL-10 in the blood and sigmoid colon mucosa and the proportion of IL-10‑positive cells in the IBS-D group were significantly lower than those in the control group (P<0.05). The levels of IL-1β in the blood and sigmoid colon mucosa and the proportion of IL-1β‑positive cells in the anxiety‑depression IBS-D group were significantly higher than those in the non‑anxiety-depression IBS-D group, and the levels of IL-10 and the proportion of IL-10‑positive cells in the anxiety-depression IBS-D group were significantly lower than those in the non-anxiety-depression IBS-D group (P<0.05). Anxiety-depression status may cause the IL-1β and IL-10 levels in IBS patients to change and result in an imbalance of the proinflammatory and anti-inflammatory cytokines, leading to the occurrence or aggravation of IBS.

View Figures

View References

1.	Occhipinti K and Smith JW: Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 25:46–52. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Lackner JM, Gudleski GD, Dimuro J, Keefer L and Brenner DM: Psychosocial predictors of self-reported fatigue in patients with moderate to severe irritable bowel syndrome. Behav Res Ther. 51:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
3.	Stasi C, Rosselli M, Bellini M, Laffi G and Milani S: Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 47:1177–85. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ and Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component. Gut. 52:91–93. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Chan J, Gonsalkorale W and Perrey M: IL-10 and TGF-beta genotype in irritable bowel syndrome: evidence to support an inflammatory component? Gastroenterology. 118:A11912000. View Article : Google Scholar
6.	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1419. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Fukudo S: Role of corticotrophin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 42:48–51. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Spiller R and Campbell E: Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 22:13–17. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Wouters MM and Boeckxstaens GE: Neuroimmune mechanisms in functional bowel disorders. Neth J Med. 69:55–61. 2011.PubMed/NCBI
10.	Camilleri M: Evolving concepts of the pathogenesis of irritable bowel syndrome: to treat the brain or the gut? J Pediatr Gastroenterol Nutr. 48(Suppl 2): S46–S48. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Sugaya N and Nomura S: Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome. Biopsychosoc Med. 2:92008. View Article : Google Scholar : PubMed/NCBI
12.	Nicholl BI, Halder SL, Macfarlane GJ, et al: Psychosocial risk markers for new onset irritable bowel syndrome - results of a large prospective population based study. Pain. 137:147–155. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Camilleri M and Fealy RD: Idiopathic autonomic denervation in eight patients presenting with functional gastrointestinal disease: A causal association? Dig Dis Sci. 35:609–616. 1990. View Article : Google Scholar
14.	Schiepers OJ, Wichers MC and Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 29:201–217. 2005. View Article : Google Scholar
15.	Smulevich AB, Rappoport SI, Syrkin AL, et al: Visceral neuroses: clinical approaches to the problem. Zh Nevrol Psikhiatr Im S S Korsakova. 102:15–21. 2002.(In Russian).
16.	Chadwick VS, Chen W, Shu D, et al: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 122:1178–1783. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Li Y, Wang Y, Zuo X, et al: Visceral perception thresholds after rectal thermal and pressure stimuli in irritable bowel syndrome patients. J Gastroenterol Hepatol. 19:187–191. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Smart HL and Atkinson M: Abnormal vagal function in irritable bowel syndrome. Lancet. 2:475–478. 1987. View Article : Google Scholar : PubMed/NCBI
19.	Dinan TG, Quigley EM, Ahmed SM, et al: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 130:304–311. 2006. View Article : Google Scholar
20.	Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 130:1377–1390. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Heller F, Florian P, Bojarski C, et al: Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 129:550–564. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Liebregts T, Adam B, Bredack C, et al: Immune activation in patients with irritable bowel syndrome. Gastroenterology. 132:913–920. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Akbar A, Yiangou Y, Facer P, Walters JR, Anand P and Ghosh S: Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 57:923–929. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Binimelis J, Webb SM and Monés J: Somatostatin and the irritable bowel syndrome. Lancet. 2:15331987. View Article : Google Scholar